Last Updated: November 18, 2026

Details for Patent: 11,951,190

« Back to Dashboard


Which drugs does patent 11,951,190 protect, and when does it expire?

Patent 11,951,190 protects PLUVICTO and is included in one NDA.

This patent has eighty-three patent family members in thirty-seven countries.

Summary for Patent: 11,951,190
Title:Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer
Abstract:The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
Inventor(s):Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike BAUDER-WÜST, Michael Eisenhut, Walter Mier, Martina BENESOVA
Assignee: Novartis AG
Application Number:US17/143,280
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 11,951,190

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis PLUVICTO lutetium lu-177 vipivotide tetraxetan SOLUTION;INTRAVENOUS 215833-001 Mar 23, 2022 RX Yes Yes 11,951,190 ⤷  Start Trial FOR TREATMENT OF ADULT PATIENTS WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WHO HAVE BEEN TREATED WITH ANDROGEN RECEPTOR PATHWAY INHIBITOR (ARPI) THERAPY ⤷  Start Trial
Novartis PLUVICTO lutetium lu-177 vipivotide tetraxetan SOLUTION;INTRAVENOUS 215833-001 Mar 23, 2022 RX Yes Yes 11,951,190 ⤷  Start Trial IN COMBINATION WITH ANDROGEN RECEPTOR PATHWAY INHIBITOR (ARPI) THERAPY FOR TREATMENT OF ADULT PATIENTS WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-POSITIVE METASTATIC ANDROGEN PATHWAY MODULATION-NAÏVE OR -SENSITIVE (MAPMN/S) PROSTATE CANCER ⤷  Start Trial
Novartis PLUVICTO lutetium lu-177 vipivotide tetraxetan SOLUTION;INTRAVENOUS 215833-001 Mar 23, 2022 RX Yes Yes 11,951,190 ⤷  Start Trial FOR TREATMENT OF ADULT PATIENTS WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-POSITIVE METASTATIC ANDROGEN PATHWAY MODULATION-RESISTANT (MAPMR) PROSTATE CANCER WHO HAVE BEEN TREATED WITH ANDROGEN RECEPTOR PATHWAY INHIBITOR (ARPI) THERAPY ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,951,190

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 4095130 ⤷  Start Trial CA 2024 00027 Denmark ⤷  Start Trial
European Patent Office 4095130 ⤷  Start Trial LUC00352 Luxembourg ⤷  Start Trial
European Patent Office 4095130 ⤷  Start Trial 301281 Netherlands ⤷  Start Trial
European Patent Office 4095130 ⤷  Start Trial PA2024522 Lithuania ⤷  Start Trial
European Patent Office 4095130 ⤷  Start Trial 2024C/528 Belgium ⤷  Start Trial
European Patent Office 4095130 ⤷  Start Trial 122024000038 Germany ⤷  Start Trial
European Patent Office 4095130 ⤷  Start Trial CR 2024 00027 Denmark ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.